Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

296 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-29

Study Completion Date

2023-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate frailty in patients aged ≥ 65 years with cancer. The elderly population is very heterogeneous, it is necessary to evaluate these elderly patients before treatment to assess the risk-benefit balance. To date, this assessment relies on subjective clinical methods often not optimal, and slow to implement. An innovative method of evaluation could be the determination of elastin peptides. Indeed, the rate of these peptides, which are linked to serious conditions associated with age, rising inexorably with age and dose could help determine more objectively the type of treatment to offer older patients.

Expected results : This study will allow better identification of the group of frail elderly through more relevant biological marker that clinical assessment, often subjective and not available within a period compatible with the treatment of newly diagnosed cancer. This biological assessment will also enable optimal management of elderly patients in particular by allowing the geriatrician better efficiency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Frailty in Elderly Patients With Advanced Cancers

NCT02482285

Cancer

TERMINATED

Approaches and Metrics in Fraily Patients During COVID-19 Era

NCT05792891

Frailty Oncology Immune Deficiency

COMPLETED

Assessment of Patient Frailty Prior to Thoracic Surgery

NCT02803281

Lung Cancer Esophageal Cancer

COMPLETED

A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.

NCT04683393

Multiple Myeloma

COMPLETED

Prediction of Esophageal and Lung Toxicities After Radiation (Chemo) Therapy

NCT04545658

Lung Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients

Group Type EXPERIMENTAL

blood withdrawn

Intervention Type BIOLOGICAL

urine collection

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood withdrawn

Intervention Type BIOLOGICAL

urine collection

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 65 years or older
* diagnosis of cancer
* affiliation to a social security scheme
* Signed informed consent for the study and for the collection of biological samples